- Home
- ETON vs MCI Comparison
ETON vs MCI Comparison
Compare ETON & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- MCI
- Stock Information
- Founded
- ETON 2017
- MCI 1971
- Country
- ETON United States
- MCI United States
- Employees
- ETON N/A
- MCI N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- MCI Trusts Except Educational Religious and Charitable
- Sector
- ETON Health Care
- MCI Finance
- Exchange
- ETON Nasdaq
- MCI Nasdaq
- Market Cap
- ETON 498.8M
- MCI 411.5M
- IPO Year
- ETON 2018
- MCI N/A
- Fundamental
- Price
- ETON $16.95
- MCI $20.71
- Analyst Decision
- ETON Strong Buy
- MCI
- Analyst Count
- ETON 3
- MCI 0
- Target Price
- ETON $29.67
- MCI N/A
- AVG Volume (30 Days)
- ETON 278.7K
- MCI 40.4K
- Earning Date
- ETON 11-06-2025
- MCI 01-01-0001
- Dividend Yield
- ETON N/A
- MCI 8.46%
- EPS Growth
- ETON N/A
- MCI N/A
- EPS
- ETON N/A
- MCI 1.82
- Revenue
- ETON $70,316,000.00
- MCI N/A
- Revenue This Year
- ETON $105.25
- MCI N/A
- Revenue Next Year
- ETON $40.84
- MCI N/A
- P/E Ratio
- ETON N/A
- MCI $9.88
- Revenue Growth
- ETON 102.77
- MCI N/A
- 52 Week Low
- ETON $8.43
- MCI $12.96
- 52 Week High
- ETON $23.00
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- ETON 38.74
- MCI 59.47
- Support Level
- ETON $16.34
- MCI $20.15
- Resistance Level
- ETON $18.15
- MCI $20.90
- Average True Range (ATR)
- ETON 1.08
- MCI 0.44
- MACD
- ETON -0.14
- MCI 0.03
- Stochastic Oscillator
- ETON 14.34
- MCI 84.20
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.